Alkermes plc (ALKS)
| Previous close | 24.34 |
| Open | 24.42 |
| Bid | 24.66 x 100 |
| Ask | 24.80 x 100 |
| Day's range | 24.34 - 24.78 |
| 52-week range | 22.01 - 33.71 |
| Volume | |
| Avg. volume | 1,872,833 |
| Market cap | 4.187B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 7.36 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings
- PR Newswire
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
- PR Newswire
Alkermes plc Reports First Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024.
